expectancy compared with other treatment options in properly selected individuals. The decision by patients to choose AS as the initial management strategy is dependent on individual preferences and plays an important role in shared decision-making. Further
Search Results
Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng, and Michael Kuettel
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
undergo surveillance unless there is compelling reason not to. However, patients with larger tumors may prefer radiation or chemotherapy if they know they have a higher risk of relapse. So tumor size can facilitate shared decision-making.” The other area
Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung
-making occurs for patients with resectable PDAC and whether specific barriers to the use of NT exist. Further data on patient and physician preferences and the patient experience during NT may highlight opportunities to improve shared decision-making and
Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico, and Mark F. Berry
-negative NSCLC in a nontrial setting, which can improve the shared decision-making process and better inform treatment recommendations. In this study, 900 patients aged 70 years or older were given AC. Although there are no specific guidelines for the treatment
Maxwell T. Vergo and Al B. Benson III
absolute benefits patients may expect from adjuvant therapy in their situation. This can be weighed against known long-term adverse effects from receiving adjuvant chemotherapy, optimizing the shared decision-making process between patient and physician
Andrew T. Kuykendall and Rami Komrokji
routinely recommend cytoreductive therapy; however, this is another situation in which shared decision-making is vital. Broadly speaking, the lack of consensus regarding the impact of platelet count in ET suggests this is a complex relationship that is
Omar Abdel-Rahman
, a shared decision-making process between physicians and patients was recommended) and because screening practices for this subgroup vary across different Canadian jurisdictions, a sensitivity analysis was conducted, repeating all analyses on women
Presenters: Benjamin O. Anderson and Janice A. Lyons
, and whose RT can be limited to the breast and not include the nodes, Dr. Lyons added. She emphasized that shared decision-making is critical in situations such as this. “The patient may want to accept a higher risk of locoregional recurrence versus
Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold, and May T. Cho
-sensitive malignancies. Thus, reports such as this highlight the potential for immunotherapy to be safely and effectively administered in this unique patient population. A thorough discussion of risks and benefits with the patient and shared decision-making are critical
has worked elsewhere, and making sure these discussions include input from patient advocates. Visit NCCN.org to learn more about the tools NCCN provides to encourage prevention and enable shared decision-making between patients and providers
